摘要
胃癌是死亡率最高的肿瘤之一。对于晚期胃癌,化疗仍是其主要的治疗手段。但是目前为止尚无标准方案。根据临床研究的进展,我们应该进一步优化化疗策略。单药化疗有效率低,不推荐用于常规化疗,但由于毒性较小,仍适用于体质状况差、无法耐受强烈化疗的患者,同时可尝试用于强烈化疗间歇期的维持治疗。两药联合化疗有效率明显高于单药化疗,同时毒副反应发生率低于三药联合,适用于大多数患者。三药联合化疗毒性反应强烈,但近期有效率最高,适用于体质较好或希望获得高有效率的患者。很多分子靶向药物已经在临床研究和应用中显示出良好的效果和治疗前景,但仍需在临床研究和实践中进一步调整和优化。
Gastric cancer is one of the fatalest cancer in the world. By now chemotherapy is the role treatment in advanced gastric cancer, but no gold standard approach has been adopted. With progress in clinical studies, we should optimize the chemotheraputic strategy. Single agent chemotherapy has less response and less survival, but less toxicity either, so it can be tried to use in patients with poor performance status, and as maintenane therapy between intensity chemotherapy in clinical trial. The response and survival of bi-agent combination are better improved, and its toxicity is not too fierce, so it can be used in most patients. Triple agent combination has fierce toxicity but best recent response, so it can be used in patients with good performance status and for the purpose of best response. A number of new molecular-targeted drugs have shown great benefit and perspective in treatment of advanced gastric cancer, but their usage should be further modified and optimized in clinical trial and practice.
出处
《临床肿瘤学杂志》
CAS
2011年第8期760-764,共5页
Chinese Clinical Oncology
关键词
晚期胃癌
化学治疗
进展
Advanced gastric cancer
Chemotherapy
Progress
